1-Benzylmethylamino-3-hexanon | 32373-06-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Benzylmethylamino-3-hexanon
• 英文别名: 1-(benzyl-methyl-amino)-hexan-3-one；1-[Benzyl(methyl)amino]-3-hexanone；1-[benzyl(methyl)amino]hexan-3-one
• CAS: 32373-06-1
• 化学式: C₁₄H₂₁NO
• 分子量: 219.327
• InChiKey: GMINVHYGAYPZBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(benzyl-methyl-amino)-heptan-3-ol 、 1-Benzylmethylamino-3-hexanon 生成 1-(benzyl-methyl-amino)-hexan-3-ol
  参考文献：
  名称：

  Propanamine derivatives as serotonin and norepinephrine reuptake inhibitors

  摘要：

  提供了一种公式（I）的取代为3-氨基丙烷基的苄氧基/硫代苄氧基化合物，其中A选择自—O—和—S—; X选择自苯基，该苯基可选地被最多5个取代基取代，每个取代基独立地选择自卤素，C1-C4烷基和C1-C4烷氧基，噻吩基，该噻吩基可选地被最多3个取代基取代，每个取代基独立地选择自卤素和C1-C4烷基，以及C2-C8烷基，C2-C8烯基，C3-C8环烷基和C4-C8环烷基烷基，每个基团可选地被最多3个取代基取代，每个取代基独立地选择自卤素，C1-C4烷基，C1-C4烷氧基，C1-C4烷基—S（O）n—，其中n为0，1或2，—CF3，—CN和—CONH2; Y选择自二氢苯并噻吩基，苯并噻唑基，苯并异噻唑基，喹啉基，异喹啉基，萘啉基和噻吩吡啶基，每个基团可选地被最多4个或在可能情况下最多5个取代基取代，每个取代基独立地选择自卤素，C1-C4烷基，C1-C4烷氧基，C1-C4烷基-S（O）n—，其中n为0，1或2，硝基，乙酰基，—CF3，—SCF3和氰基; Z选择自H，OR3或F，其中R3选择自H，C1-C6烷基和苯基C1C6烷基; R1和R2各自独立地选择自H或C1-C4烷基;以及其药学上可接受的盐。

  公开号：

  US07410982B2
• 作为产物：
  描述：

  1-己酮 、 N-甲基苄胺 在 CeCl₃-NaI on SiO₂ 作用下， 反应 5.0h， 以88%的产率得到1-Benzylmethylamino-3-hexanon
  参考文献：
  名称：

  Conjugate Addition of Amines to α,β-Enones Promoted by CeCl₃·7H₂O−NaI System Supported in Silica Gel

  摘要：

  DOI：

  10.1021/jo0108764

文献信息

• [EN] 3-ARYLOXY/THIO-3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPHINEPHRINE REUPTAKE<br/>[FR] COMPOSES PHARMACEUTIQUES
  申请人：LILLY CO ELI

  公开号：WO2004043904A1

  公开（公告）日：2004-05-27

  There is provided a compound of formula (I) wherein A is selected from -O- and -S-; X is selected from C2-C8 alkyl, C2-C8 alkenyl, C3-C8 cycloalkyl and C4-C8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, -CF3, -CN and -CONH2; Y is selected from phenyl, naphthyl, dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, indanyl, 1,3-benzodioxolyl, benzothienyl, indolyl and benzofuranyl, each of which may be optionally substituted with up to 4 or, where possible, 5 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, nitro, acetyl, -CF3, -SCF3 and cyano; and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from C1-C4 alkyl; Z is selected from H, OR3 or F, wherein R3 is selected from H, C1-C6 alkyl and phenyl C1-C6 alkyl; R1 and R2 are each independently H or C1-C4 alkyl; with the proviso that, when Z is H, then Y may not be optionally substituted phenyl or optionally substituted naphthyl.

  提供一种具有以下结构的化合物（I）：其中A从-O-和-S-中选择；X从C2-C8烷基，C2-C8烯基，C3-C8环烷基和C4-C8环烷基烷基中选择，每种基团可能分别被选自卤素，C1-C4烷基，C1-C4烷氧基，C1-C4烷基-S(O)n-（其中n为0，1或2），-CF3，-CN和-CONH2的最多3个取代基所取代；Y从苯基，萘基，二氢苯并噻吩基，苯并噻唑基，苯并异噻唑基，喹啉基，异喹啉基，萘啉基，噻吩吡啉基，茚基，1,3-苯并二氧杂环戊基，苯并噻吩基，吲哚基和苯并呋喃基中选择，每种基团可能分别被选自卤素，C1-C4烷基，C1-C4烷氧基，C1-C4烷基-S(O)n-（其中n为0，1或2），硝基，乙酰基，-CF3，-SCF3和氰基的最多4个或在可能的情况下5个取代基所取代；当Y为吲哚基时，它可以被选自C1-C4烷基的N-取代基取代或进一步取代；Z从H，OR3或F中选择，其中R3从H，C1-C6烷基和苯基C1-C6烷基中选择；R1和R2分别独立地为H或C1-C4烷基；但是，当Z为H时，Y可能不是可选择地取代的苯基或可选择地取代的萘基。
• [EN] PROPANAMINE DERIVATIVES AS SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS<br/>[FR] DERIVES DE PROPANAMINE UTILISES EN TANT QU'INIHIBITEURS DU RECAPTAGE DE LA SEROTONINE ET DE LA NOREPINEPHRINE
  申请人：LILLY CO ELI

  公开号：WO2004043931A1

  公开（公告）日：2004-05-27

  There is provided a heretoaryloxy/thio 3-substituted propanamine compound of formula (I) wherein A is selected from -O- and -S-; X is selected from phenyl optionally substituted with up to 5 substituents each independently selected from halo, C1-C4 alkyl and C1-C4 alkoxy, thienyl optionally substituted with up to 3 substituents each independently selected from halo and C1-C4 alkyl, and C2-C8 alkyl, C2-C8 alkenyl, C3-C8 cycloalkyl and C4-C8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, -CF3, -CN and -CONH2; Y is selected from dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, and thienopyridyl, each of which may be optionally substituted with up to 4 or, where possible, up to 5 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, nitro, acetyl, -CF3, -SCF3 and cyano; Z is selected from H, OR3 or F, wherein R3 is selected from H, C1-C6 alkyl and phenyl C1-C6 alkyl; R1 and R2 are each independently H or C1-C4 alkyl; and pharmaceutically acceptable salts thereof.

  提供了一种公式（I）的醚/硫代3-取代丙胺化合物，其中A选自-O-和-S-；X选自苯基，可选地取代为最多5个取代基，每个取代基独立选自卤素、C1-C4烷基和C1-C4烷氧基，噻吩基，可选地取代为最多3个取代基，每个取代基独立选自卤素和C1-C4烷基，以及C2-C8烷基，C2-C8烯基，C3-C8环烷基和C4-C8环烷基烷基，每个基可选地取代为最多3个取代基，每个取代基独立选自卤素、C1-C4烷基、C1-C4烷氧基、C1-C4烷基-S(O)n-其中n为0、1或2、-CF3、-CN和-CONH2；Y选自二氢苯并噻吩基，苯并噻唑基，苯并异噻唑基，喹啉基，异喹啉基，萘啉基和噻吩吡啉基，每个基可选地取代为最多4个或在可能的情况下，最多5个取代基，每个取代基独立选自卤素、C1-C4烷基、C1-C4烷氧基、C1-C4烷基-S(O)n-其中n为0、1或2、硝基、乙酰基、-CF3、-SCF3和氰基；Z选自H、OR3或F，其中R3选自H、C1-C6烷基和苯基C1-C6烷基；R1和R2各自独立地为H或C1-C4烷基；以及其药学上可接受的盐。
• LSD1 Inhibitors
  申请人：Mirati Therapeutics, Inc.

  公开号：US20170183308A1

  公开（公告）日：2017-06-29

  The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

  本发明涉及抑制LSD1活性的化合物。具体而言，本发明涉及化合物、药物组合物和使用方法，例如使用本发明的化合物和药物组合物治疗癌症的方法。
• 3-Aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norephinephrine reuptake
  申请人：Boulet Louis Serge

  公开号：US20060014779A1

  公开（公告）日：2006-01-19

  There is provided a compound of formula (I) wherein A is selected from —O— and —S—; X is selected from C 2 -C 8 alkyl, C 2 -C 8 alkenyl, C 3 -C 8 cycloalkyl and C 4 -C 8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 alkyl-S(O) n — where n is 0, 1 or 2 , —CF 3 , —CN and —CONH 2 ; Y is selected from phenyl, naphthyl, dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, indanyl, 1,3 -benzodioxolyl, benzothienyl, indolyl and benzofuranyl, each of which may be optionally substituted with up to 4 or, where possible, 5 substituents each independently selected from halo, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 alkyl-S(O) n — where n is 0, 1 or 2 , nitro, acetyl, —CF 3 , —SCF 3 and cyano; and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from C 1 -C 4 alkyl; Z is selected from H, OR 3 or F, wherein R 3 is selected from H, C 1 -C 6 alkyl and phenyl C 1 -C 6 alkyl; R 1 and R 2 are each independently H or C 1 -C 4 alkyl; with the proviso that, when Z is H, then Y may not be optionally substituted phenyl or optionally substituted naphthyl.

  提供了一种化合物，其化学式为（I），其中A从—O—和—S—中选择；X从C2-C8烷基，C2-C8烯基，C3-C8环烷基和C4-C8环烷基烷基中选择，每种基团均可选用最多3个取代基，每个取代基可独立地从氯，C1-C4烷基，C1-C4烷氧基，C1-C4烷基-S（O）n-其中n为0，1或2，—CF3，—CN和—CONH2中选择；Y从苯基，萘基，二氢苯并噻吩基，苯并噻唑基，苯并异噻唑基，喹啉基，异喹啉基，萘啉基，噻吩基，茚基，1,3-苯并二氧杂环基，苯并噻吩基，吲哚基和苯并呋喃基中选择，每种基团均可选用最多4个或在可能的情况下最多5个取代基，每个取代基可独立地从氯，C1-C4烷基，C1-C4烷氧基，C1-C4烷基-S（O）n-其中n为0，1或2，硝基，乙酰基，—CF3，—SCF3和氰基中选择；当Y为吲哚基时，它可以被一个N-取代基所取代，所述取代基从C1-C4烷基中选择；Z从H，OR3或F中选择，其中R3从H，C1-C6烷基和苯基C1-C6烷基中选择；R1和R2各自独立地为H或C1-C4烷基；但是，当Z为H时，Y可能不是可选取代的苯基或可选取代的萘基。
• Propanamine derivatives as serotonin and norepinephrine reuptake inhibitors
  申请人：Boulet Louis Serge

  公开号：US20060058360A1

  公开（公告）日：2006-03-16

  There is provided a heretoaryloxy/thio 3-substituted propanamine compound of formula (I) wherein A is selected from —)— and —S—; X is selected from phenyl optionally substituted with up to 5 substituents each independently selected from halo, C 1 -C 4 alkyl and C 1 -C 4 alkoxy, thienyl optionally substituted with up to 3 substituents each independently selected from halo and C 1 -C 4 alkyl, and C 2 -C 8 alkyl, C 2 -C 8 alkenyl, C 3 -C 8 cycloalkyl and C 4 -C 8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 alkyl —S(O) n — where n is 0, 1 or 2, —CF 3 , —CN and —CONH 2 ; Y is selected from dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, and thienopyridyl, each of which may be optionally substituted with up to 4 or, where possible, up to 5 substituents each independently selected from halo, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 alkyl-S(O) n — where n is 0, 1 or 2 , nitro acetyl, —CF 3 , —SCF 3 and cyano; Z is selected from H, OR 3 or F, wherein R 3 is selected from H, C 1 -C 6 alkyl and phenyl C 1 C 6 alkyl; R 1 and R 2 are each independently H or C 1 -C 4 alkyl; and pharmaceutically acceptable salts thereof.

  提供了一种公式（I）的取代了3-氨基丙烷基的heretoaryloxy/thio化合物，其中A选自—）—和—S—; X选自苯基，其可选地被最多5个取代基独立地选自卤素、C1-C4烷基和C1-C4烷氧基取代，噻吩基，其可选地被最多3个取代基独立地选自卤素和C1-C4烷基取代，以及C2-C8烷基，C2-C8烯基，C3-C8环烷基和C4-C8环烷基烷基，每个基团可选地被最多3个取代基独立地选自卤素，C1-C4烷基，C1-C4烷氧基，C1-C4烷基—S（O）n—其中n为0,1或2，—CF3，—CN和—CONH2; Y选自二氢苯并噻吩基，苯并噻唑基，苯并异噻唑基，喹啉基，异喹啉基，萘啉基和噻吩吡啶基，每个基团可选地被最多4个或，如果可能，最多5个取代基独立地选自卤素，C1-C4烷基，C1-C4烷氧基，C1-C4烷基-S（O）n—其中n为0,1或2，硝基乙酰基，—CF3，—SCF3和氰基; Z选自H，OR3或F，其中R3选自H，C1-C6烷基和苯基C1C6烷基; R1和R2各自独立地为H或C1-C4烷基;以及其药学上可接受的盐。